Kedrion Biopharma

Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.

HUMAN ALBUMIN - pharmacyneeds

Prothrombin Complex Concentrates Market Growth in Future Scope

Kedrion Biopharma studies anti-coronavirus therapy - Invest in Tuscany

Kedrion Biopharma redeems €200m of its notes that fall due in 2022

FSI invests in Kedrion

Dal dono al farmaco salvavita, AVIS incontra Kedrion - Iostudio

Kedrion Biopharma - GBS/CIDP Foundation International

Kedrion Biopharma 00562780525 - McKesson Medical-Surgical

Kedrion Biopharma · 4 of 30 · Christian Sinibaldi

Anekant Pharmaceuticals Private Limited - VenBig 500 IU

00562780525 - Henry Schein Medical

Kedrion Human Albumin, For Hospital, 30 Degree Celsius

Cisco Case Study: Kedrion Biopharma - Cisco